StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
SAGE Therapeutics (SAGE) Climbs 50% After Phase 3 Study to Treat Postpartum Depression Meets Primary Endpoint
November 9, 2017 6:42 AM
SAGE Therapeutics (NASDAQ: SAGE) ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
FDA
Hot FDA News
Trader Talk
Next Articles
Chardan Capital Markets Upgrades Sage Therapeutics (SAGE) to Buy
November 10, 2017 8:16 AM
Sage Therapeutics (SAGE) PT Raised to $135 at Cowen
November 9, 2017 3:20 PM
Sage Therapeutics (SAGE) PT Raised to $105 at Stifel
November 9, 2017 12:43 PM
Sage Therapeutics (SAGE) PT Raised to $123 at Leerink Partners
November 9, 2017 12:13 PM
Sage Therapeutics (SAGE) PT Raised to $100 at Needham & Company
November 9, 2017 11:34 AM
Sage Therapeutics (SAGE) Hits 'Very Significant Milestone' - BMO
November 9, 2017 10:12 AM
SAGE Therapeutics (SAGE) Says Brexanolone Achieved Primary Endpoints in Both Phase 3 Trials in Postpartum Depression
November 9, 2017 6:28 AM
Sage Therapeutics Announces Brexanolone Achieves Primary Endpoints in Both Phase 3 Clinical Trials in Postpartum Depression
November 9, 2017 6:00 AM
